Andere Sprachen Akero Therapeutics, Inc.

Aktien

A2PLNP

US00973Y1082

AKRO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
20,08 ^USD	+0,96 %		-0,89 %	-14,00 %

30.04.	Akero Therapeutics ernennt Scott Gangloff zum Chief Technology Officer	CI
07.03.	Akero Therapeutics, Inc. gibt die Veröffentlichung der Ergebnisse der Phase 2b SYMMETRY Kohorte D Studie in Clinical Gastroenterology and Hepatology bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AKRO Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	03:42
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm	01.05.
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.	01.05.
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.	01.05.
AKRO ROSEN, A TOP RANKED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -AKRO	01.05.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics	01.05.
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer	30.04.
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer	30.04.
Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO	29.04.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO	29.04.
AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit	29.04.
AKERO THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO	28.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO	28.04.
6 Stocks Positioned to Soar as Investors Focus on MASH	22.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO	20.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO	05.04.
Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.	03.04.
Akero Therapeutics Raises $367 Million From Share Offering	08.03.
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares	08.03.
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares	08.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Akero Therapeutics, Inc.

Aktien

A2PLNP

US00973Y1082

AKRO

Andere Sprachen

Filter